PNC Financial Services Group Inc. Raises Position in Jazz Pharmaceuticals PLC (JAZZ)

PNC Financial Services Group Inc. boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 381.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,530 shares of the specialty pharmaceutical company’s stock after purchasing an additional 43,209 shares during the period. PNC Financial Services Group Inc. owned about 0.09% of Jazz Pharmaceuticals worth $9,395,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of JAZZ. Daiwa Securities Group Inc. lifted its stake in Jazz Pharmaceuticals by 22.7% in the 1st quarter. Daiwa Securities Group Inc. now owns 2,331 shares of the specialty pharmaceutical company’s stock valued at $352,000 after purchasing an additional 431 shares during the last quarter. SG Americas Securities LLC acquired a new position in Jazz Pharmaceuticals in the 1st quarter valued at approximately $1,178,000. State Board of Administration of Florida Retirement System increased its position in Jazz Pharmaceuticals by 25.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 4,697 shares of the specialty pharmaceutical company’s stock valued at $709,000 after acquiring an additional 966 shares during the period. LSV Asset Management increased its position in Jazz Pharmaceuticals by 44.6% in the 1st quarter. LSV Asset Management now owns 230,670 shares of the specialty pharmaceutical company’s stock valued at $34,828,000 after acquiring an additional 71,100 shares during the period. Finally, Financial Gravity Wealth Inc. acquired a new position in Jazz Pharmaceuticals in the 1st quarter valued at approximately $192,000. 92.56% of the stock is owned by institutional investors and hedge funds.

JAZZ opened at $168.80 on Friday. Jazz Pharmaceuticals PLC has a twelve month low of $128.58 and a twelve month high of $184.00. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54. The firm has a market cap of $10.35 billion, a PE ratio of 17.66, a PEG ratio of 0.93 and a beta of 1.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.23 by $0.26. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. The company had revenue of $500.48 million during the quarter, compared to analysts’ expectations of $469.85 million. research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.7 earnings per share for the current fiscal year.

Several equities analysts have issued reports on the stock. BidaskClub cut shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 28th. Stifel Nicolaus upped their price target on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. B. Riley upped their price target on shares of Jazz Pharmaceuticals from $211.00 to $219.00 and gave the company a “buy” rating in a research report on Tuesday, June 26th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Monday, July 2nd. Finally, BMO Capital Markets upped their price target on shares of Jazz Pharmaceuticals from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Wednesday, August 8th. One analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $190.71.

In other news, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $176.53, for a total transaction of $35,306.00. Following the completion of the sale, the executive vice president now directly owns 25,972 shares in the company, valued at $4,584,837.16. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Rick E. Winningham sold 16,639 shares of the stock in a transaction on Friday, August 10th. The stock was sold at an average price of $176.18, for a total transaction of $2,931,459.02. Following the sale, the director now owns 15,594 shares of the company’s stock, valued at $2,747,350.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,848 shares of company stock valued at $4,190,824. 3.90% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Tariff

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply